Subsequent studies in sporadic meningiomas demonstrated that up to 60% of these cases exhibit inactivation of NF2 by somatic mutation, epigenetic inactivation, or allelic loss of chr22q [23,24,25,26]. This evidence concerns the gene NF2 and meningioma.